Ozempic® Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza® and Canagliflozin in People With Type 2 Diabetes

Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk announced today
the results from two Ozempic® (once-weekly semaglutide 1.0 mg)
head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which
showed:

- Ozempic® was superior to treatment with the SGLT-2 inhibitor
canagliflozin (300 mg) in reducing HbA1c and body weight in people
with type 2 diabetes uncontrolled on metformin.1
- Ozempic® was superior to Victoza® (liraglutide 1.2 mg) in reducing
HbA1c and body weight in people with type 2 diabetes.2

These data were presented at the European Association for the
Study of Diabetes (EASD) Annual Meeting in Barcelona, and
simultaneously published in The Lancet Diabetes & Endocrinology
(SUSTAIN 8) and Diabetes and Metabolism (SUSTAIN 10).1,2

"We are proud of the superior clinical profile of once-weekly
Ozempic®, as demonstrated through all the SUSTAIN clinical trials,
and encouraged by these new data which further reinforce the value of
Ozempic® for people with type 2 diabetes," said Mads Krogsgaard
Thomsen, executive vice president and chief science officer of Novo
Nordisk.

These trials form part of the extensive SUSTAIN programme, a
global clinical development programme that comprises more than 10
Phase 3 trials involving more than 10,065 adults with type 2
diabetes. To date, outcomes of SUSTAIN 1-7 and 9 have been published
demonstrating Ozempic® is a best-in-class, efficacious and
well-tolerated treatment option for people with type 2 diabetes.

SUSTAIN 81

At 52 weeks, Ozempic® demonstrated a superior reduction in mean
HbA1c of 1.5% compared to canagliflozin at 1.0%, from a baseline of
8.3%. In addition, 66.1% of people treated with Ozempic® achieved
HbA1c treatment target <7% vs 45.1% of those treated with
canagliflozin. People treated with Ozempic® also demonstrated
superior reductions in body weight compared with canagliflozin with
5.3 kg vs 4.2 kg, respectively, from a mean baseline of 90.2 kg.
Significantly more people treated with Ozempic® achieved reduction in
body weight of >=10% vs canagliflozin (22.3% vs 8.9%, respectively).

"To date, head-to-head trials of GLP-1 receptor agonists and
SGLT-2 inhibitors have been limited," said Dr Ildiko Lingvay,
University of Texas Southwestern Medical Centre, Dallas, and lead
study investigator. "These data seen in the SUSTAIN 8 trial support
Ozempic® as an efficacious treatment option for reducing blood sugar
and body weight for people with type 2 diabetes after metformin."

SUSTAIN 102

At 30 weeks, Ozempic® demonstrated a superior reduction in mean
HbA1c compared to Victoza® (1.7% vs 1.0% respectively), from a mean
baseline of 8.2%. In addition, 80% of people treated with Ozempic®
achieved HbA1c treatment target of <7% vs 46% of those treated with
Victoza®. People treated with Ozempic® also demonstrated superior
reductions in body weight compared with Victoza® with 5.8 kg vs 1.9
kg, respectively, from a mean baseline of 96.9 kg. Significantly more
people treated with Ozempic® achieved reduction in body weight of
>=10% than those treated with Victoza® (19% vs 4%, respectively).

"Intensifying treatment with Ozempic® showed significant benefits
over Victoza® in terms of blood sugar control and reduction in body
weight, providing an alternative treatment option for those
uncontrolled on current treatment," said Dr Matthew Capehorn,
Rotherham Institute for Obesity, UK, and lead study investigator.

The tolerability of once-weekly Ozempic® was generally similar to
that of Victoza® and canagliflozin, except for higher rates of
gastrointestinal adverse events (AEs) with Ozempic® vs Victoza® and
more frequent infections and infestations with canagliflozin vs
Ozempic®. The safety profile of Ozempic® 1.0 mg in both trials was
consistent with the overall SUSTAIN clinical trial programme.

About Ozempic®

Once-weekly Ozempic® (semaglutide) is an analogue of human
glucagon-like peptide-1 (GLP-1) indicated as an adjunct to diet and
exercise to improve glycaemic control in adults with type 2
diabetes.3,4 Ozempic® was first approved by the US FDA in 2017 and is
now launched in 25 countries.

About SUSTAIN 8

SUSTAIN 8 is a 52-week double-blinded Phase 3 trial investigating
the efficacy and safety of once-weekly Ozempic® (semaglutide 1.0 mg)
vs canagliflozin 300 mg as add-on to metformin in people with type 2
diabetes. The primary endpoint was change in HbA1c from baseline to
Week 52, and key secondary endpoints include change in body weight at
Week 52 and proportion of people achieving HbA1c <7.0% (53 mmol/mol)
at Week 52.1

About SUSTAIN 10

SUSTAIN 10 is a 30-week open-label Phase 3b trial investigating
the safety and efficacy of Ozempic® 1.0 mg once-weekly vs Victoza®
1.2 mg once-daily, as add-on to 1-3 oral antidiabetics (OADs) in 577
adults with type 2 diabetes in Europe. The primary endpoint was
change in HbA1c at Week 30, and key secondary endpoints include
change in body weight at Week 30 and proportion of people achieving
HbA1c <7.0% (53 mmol/mol) at Week 30.2

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95
years of innovation and leadership in diabetes care. This heritage
has given us experience and capabilities that also enable us to help
people defeat obesity, haemophilia, growth disorders and other
serious chronic diseases. Headquartered in Denmark, Novo Nordisk
employs approximately 41,600 people in 80 countries and markets its
products in more than 170 countries. For more information, visit
novonordisk.com (https://www.novonordisk.com/), Facebook
(http://www.facebook.com/novonordisk), Twitter
(http://www.twitter.com/novonordisk), LinkedIn
(http://www.linkedin.com/company/novo-nordisk), YouTube
(http://www.youtube.com/novonordisk).

References

1. Lingvay I, et al. Efficacy and safety of once-weekly semaglutide
versus daily canagliflozin as add-on to metformin in patients with
type 2 diabetes (SUSTAIN 8): a double-blind, randomised,
controlled trial. The Lancet Diabetes & Endocrinology. Published
Online 17 September 2019. http://dx.doi.org/10.1016/PII
2. Capehorn MS, et al. Efficacy and safety of once-weekly semaglutide
1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral
antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Diabetes Metab (2019).
https://doi.org/10.1016/j.diabet.2019.101117
3. EMA. Ozempic® Summary of Product Characteristics. Available at: ht
tp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/004174/WC500244163.pdf. Last accessed: September
2019.
4. FDA. Ozempic® US Prescribing Information. December 2017. Available
at: http://www.novo-pi.com/ozempic.pdf Last accessed: September
2019.

Further information

Media:
Mette Kruse +45 mkd@novonordisk.com
Danielsen 3079
3883
Ken +1 kiau@novonordisk.com
Inchausti 609
(US) 240
9429
Investors:
Peter +45 phak@novonordisk.com
Hugreffe 3075
Ankersen 9085
Kristoffer +1 krdb@novonordisk.com
Due Berg 609
(US) 235
2989
Valdemar +45 jvls@novonordisk.com
Borum 3079
Svarrer 0301
Ann +45 arnd@novonordisk.com
Søndermølle 3075
Rendbæk 2253

ots Originaltext: Novo Nordisk A/S
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Novo Nordisk A/S, übermittelt durch news aktuell